Genomics For Precision Medicine: Bridging Research And Clinical Practice

Abstract

Introduction: The advent of genomics has accelerated the development of precision medicine, enabling individualized diagnosis and therapy. Precision medicine integrates genomic insights to optimize diagnosis, prognosis, and treatment tailored to individual variability. Despite advances in next-generation sequencing (NGS) and bioinformatics, the translation of genomic research into clinical settings remains uneven. With advances in next-generation sequencing, multi-omics integration, and gene editing, genomics is now central to translating molecular discoveries into clinical practice.

Materials and Methods: A prospective, multicenter observational study was designed, enrolling 500 patients with cancer, cardiovascular, and rare genetic disorders. Inclusion criteria were adults aged 18–70 years who consented to genomic testing; exclusion criteria included severe comorbidities limiting survival below 6 months. Whole-exome sequencing (WES) and targeted gene panels were performed. Clinical decision-making pre- and post-genomic testing was compared.

Results: Genomic testing altered clinical management in 42% of cases. Pathogenic variants were identified in 36% of patients, with cancer patients showing the highest yield. Pharmacogenomic testing guided drug choice in 28% of cases. Six summary tables demonstrate variant detection rates, disease-wise distribution, cost-effectiveness, and clinical impact.

Conclusion: Genomic medicine substantially bridges research and clinical care, with demonstrable improvements in diagnosis, therapy optimization, and patient outcomes. However, integration requires robust infrastructure, ethical frameworks, and clinician education.